Key facts
- This page summarizes Ansbert Gadicke's Form 5 filing for Cullinan Oncology, Inc. (CGEM).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 10 Feb 2023, 15:26.
Ansbert Gadicke - 31 Dec 2021 Form 5 Insider Report for Cullinan Oncology, Inc. (CGEM)
- Reporting relationship
- Former Director, 10%+ Owner
- Issuer ticker
- CGEM
- Reported as of
- 31 Dec 2021
- Net transaction value
- +$1,509,033
- SEC form
- 5
- Accepted by SEC
- 10 Feb 2023, 15:26:45 UTC
- Prior SEC filing
- 07 Dec 2021
- Next SEC filing
- 06 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ansbert Gadicke
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Ansbert Gadicke filed Form 5 for Cullinan Oncology, Inc. (CGEM) on 10 Feb 2023.
Change
- Previous filing in this sequence was filed on 07 Dec 2021.
- Current net transaction value: +$1,509,033.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 5 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CGEM
transaction
Common Stock
Options Exercise
- Transaction value
- $1,509,033
- Shares
- +350,938
- Change %
- +144%
- Price
- $4.30
- Shares after
- 595,489
- Date
- 21 Dec 2021
- Ownership
- Direct
CGEM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 7,648,268
- Date
- 31 Dec 2021
- Ownership
- See Footnote
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CGEM
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -262,114
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 262,114
- Exercise price
- $4.30
- Footnotes
- F3
CGEM
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -88,824
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 Dec 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 88,824
- Exercise price
- $4.30
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These securities are owned directly by UBS Oncology Impact Fund LP ("OIF"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. ("OIF GP"). The general partner of OIF GP is BioImpact Capital LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing partner of BioImpact Capital LLC.
Footnote F2
The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
Footnote F3
These options are fully vested.